T-VIVA-19

T-VIVA-19 Vaccine

Sorrento is developing a Protein Vaccine T-VIVA-19 against of SARS-CoV-2. T-VIVA-19 employs the fusion protein rS1-Fc, designed to target Fc-receptor expressing antigen-presenting cells for enhanced and effective induction of anti-SARS-CoV-2 neutralizing antibodies and T cell responses.